<DOC>
	<DOCNO>NCT00515307</DOCNO>
	<brief_summary>Patients homozygous familial hypercholesterolemia high serum cholesterol level despite receive lipid lower drug ( e.g . statin , etc ) . Most patient die age 20 due myocardial infarction , etc . Orthotopic liver transplantation ( OLT ) effective treatment . Hepatocyte transplantation alternative OLT may help overcome shortage donor organ . There report successful treatment different kind metabolic liver disorder hepatocyte transplantation . The major problem hepatocyte transplantation source hepatocytes limit . Bone marrow stem cell potential source hepatocytes . In in-vitro culture system successful efficient transdifferentiation mesenchymal stem cell hepatocytes documented . We already show infusion mesenchymal stem cell safe feasible cirrhosis ( Mohamadnejad M , et al . Arch Iran Med 2007 ; In Press ) . In study , 2 patient homozygous familial hypercholesterolemia include . The bone marrow healthy volunteer normal lipid profile take , bone marrow mesenchymal stem cell ( MSCs ) culture , MSCs trans-differentiate hepatocytes , cell infuse portal vein patient . The duration follow 6 month post-transplantation .</brief_summary>
	<brief_title>Bone Marrow Stem Cells Source Allogenic Hepatocyte Transplantation Homozygous Familial Hypercholesterolemia</brief_title>
	<detailed_description>Patients homozygous familial hypercholesterolemia high serum cholesterol level despite receive lipid lower drug ( e.g . statin , etc ) . Most patient die age 20 due myocardial infarction , etc . Orthotopic liver transplantation ( OLT ) effective treatment decrease serum cholesterol near normal level ( Bilheimer DW , N Engl J Med 1984 ; 311:1658-64 ) . Shortage donor organ major problem OLT . Hepatocyte transplantation alternative OLT may help overcome shortage donor organ . There report successful treatment different kind metabolic liver disorder ( Crigler Najjar Syndrome ( Fox IJ , et al . N Engl J Med 1998 ; 338:1422-6 ) , Factor VII deficiency ( Dhawan A et al . Transplantation 2004:78:1812-4 ) , Glycogen storage disease type Ia ( Muraca M , et al . Lancet 2002 ; 359:317-8 ) , etc ) hepatocyte transplantation . The major problem hepatocyte transplantation source hepatocytes limit . Bone marrow stem cell potential source hepatocytes . Although , in-vivo system controversy stem cell transdifferentiate hepatocytes fusion stem cell hepatocytes occur , however , in-vitro culture system successful efficient transdifferentiation mesenchymal stem cell hepatocytes document ( Lee KD , et al . Hepatology 2004 ; 40:1275-1284 ; &amp; Banas A , et al . Hepatology . 2007 ; 46:219-28 ) . We already show infusion mesenchymal stem cell safe feasible cirrhosis ( Mohamadnejad M , et al . Arch Iran Med 2007 ; In Press ) . In study , 2 female patient homozygous familial hypercholesterolemia include . The bone marrow ABO compatible healthy male volunteer normal lipid profile take , bone marrow mesenchymal stem cell ( MSCs ) culture , MSCs trans-differentiate hepatocytes in-vitro culture system . Then cell infuse portal vein patient . The duration follow 6 month post-transplantation .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Severe hypercholesterolemia unresponsive lipid lower agent ( e.g . statin ) Presence tendon xanthoma Documentation homozygous familial hypercholesterolemia appropriate genetic test Female gender Male gender</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Hypercholesterolemia , Familial</keyword>
	<keyword>Bone marrow</keyword>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>Hepatocyte</keyword>
</DOC>